<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596410</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0556</org_study_id>
    <nct_id>NCT04596410</nct_id>
  </id_info>
  <brief_title>Photobiomodulation Protocols in the Analgesia of Chemotherapy-induced Oral Mucositis in Children</brief_title>
  <acronym>CURALASE01</acronym>
  <official_title>Double-blind, Randomized, Multi-center, Non-inferiority Clinical Trial Comparing Two Photobiomodulation Protocols in the Analgesia of Chemotherapy-induced Oral Mucositis in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy-induced oropharyngeal mucositis (OM) negatively impacts the quality of life of&#xD;
      adult and pediatric patients by causing pain, dysphagia, dysgeusia and dysphonia.&#xD;
&#xD;
      Photobiomodulation (PBM) by low level laser therapy (LLLT), light therapy of low level of red&#xD;
      and infrared wavelengths (630-1000 nm) has been recommended since 2014 in patients treated&#xD;
      with high-dose chemotherapy for bone marrow transplantation. Available pediatric studies&#xD;
      highlighted positive/promising results of PBM with excellent safety and no adverse effects.&#xD;
      Nevertheless, a wide variety of application parameters is described in the literature, with&#xD;
      no consensus guidelines.&#xD;
&#xD;
      Considering the lack of standardized protocol of photobiomodulation in the pediatric&#xD;
      population as well as the burden and cost of a daily application, investigators have decided&#xD;
      to conduct, for the first time in children of 3 years of age or older, a multicenter,&#xD;
      randomized, double-blind, non-inferiority clinical trial to compare two PBM protocols with&#xD;
      same PBM parameters, combining red and infrared wavelengths, but with different frequencies&#xD;
      of laser application (daily versus every other day), in the treatment of chemotherapy-induced&#xD;
      OM of WHO grade 2 or higher.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Session evaluation</measure>
    <time_frame>Throught treatment period up to 1 month</time_frame>
    <description>Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Production costs evaluation</measure>
    <time_frame>2 months</time_frame>
    <description>Production costs from the hospital perspective and efficacy (i.e. number of days after which a child has no longer mucositis related pain as described in the primary endpoint section) to build Incremental Cost-Effectiveness Ratio (ICER) comparing every other day LLLT application versus with daily LLLT application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health insurance evaluation</measure>
    <time_frame>2 months</time_frame>
    <description>Costs of inpatient hospital stays from the French health insurance perspective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OM duration evaluation</measure>
    <time_frame>Throught treatment period up to 1 month</time_frame>
    <description>Duration (in days) of chemotherapy-induced OM of WHO grade 2 or higher between the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM at 2 consecutive measurements before the next scheduled PBM session (either every other day application or daily application).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OM occurrence</measure>
    <time_frame>2 months</time_frame>
    <description>Occurrence of chemotherapy-induced OM of WHO grade 3 or 4 (deterioration of the clinical situation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feed evaluation</measure>
    <time_frame>2 months</time_frame>
    <description>Occurrence of enteral feeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption</measure>
    <time_frame>2 months</time_frame>
    <description>Duration (in days) of consumption of step 2 and step 3 analgesics during chemotherapy-induced OM of WHO grade 2 or higher.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBM evaluation</measure>
    <time_frame>Through treatment period up to 1 month</time_frame>
    <description>Duration (in days) from the day of first PBM session up to the day of first measurement when patient has no longer WHO grade 2 or higher chemotherapy-induced OM related pain at 2 consecutive measurements before the next scheduled PBM session (either active laser application or matching placebo application) as evaluated, regardless of patient's age, with the ChIMES scale and use of step 3 analgesics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain change evaluation</measure>
    <time_frame>From baseline to each day of PBM session</time_frame>
    <description>Change over time in WHO grade 2 or higher chemotherapy-induced OM related pain, as assessed by pain scales (HEDEN (Hétero Evaluation Douleur Enfant) mucositis scale (5 items ranging from 0 to 2) or VAS (ranging from 0 to 10)depending on patient's age category, and Children's International Mucositis Evaluation Scale (4 items ranging from 0 to 5) whatever patient's age category)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events occurrence</measure>
    <time_frame>2 months</time_frame>
    <description>Occurrence of adverse events reported according to descriptions and grading scale found in NCI CTCAE version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thyroid-stimulating hormone (TSH) evolution</measure>
    <time_frame>From baseline to 2 months</time_frame>
    <description>TSH shift from baseline value classified according to the following three categories: &quot;&lt; 0.4 IU/mL&quot;, &quot;[0.4 - 10] IU/mL&quot;, &quot;&gt; 10 IU/mL&quot;, to value at D14-31 after end of WHO grade 2 or higher chemotherapy-induced OM classified according to the same three categories.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Mucositis Oral</condition>
  <arm_group>
    <arm_group_label>LLLT applied every other day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LLLT applied daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>LLLT applied every other day</intervention_name>
    <description>Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day</description>
    <arm_group_label>LLLT applied every other day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>LLLT applied daily</intervention_name>
    <description>Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily</description>
    <arm_group_label>LLLT applied daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female children aged ≥ 3 years and &lt; 18 years.&#xD;
&#xD;
          2. Hospitalization in an oncology or hematology department in the participating centres.&#xD;
&#xD;
          3. Patients with oropharyngeal mucositis of grade 2 or higher (WHO grading system)&#xD;
             related to cancer chemotherapy, including conditioning for Hematopoietic Stem Cell&#xD;
             Transplantation (HSCT).&#xD;
&#xD;
          4. Written informed consent of both patient's holders of parental authority, and&#xD;
             patient's assent when applicable.&#xD;
&#xD;
          5. Patients affiliated to a French Social Security insurance or equivalent social&#xD;
             protection.&#xD;
&#xD;
          6. Absence of any physical or psychological disability that may interfere with the LLLT&#xD;
             application.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a solid cancer lesion in the area of low-level laser application.&#xD;
&#xD;
          2. History of cervicofacial radiotherapy.&#xD;
&#xD;
          3. Application of low-level laser therapy for oral mucositis within 2 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          4. Hyperthyroidism defined by TSH &lt; 0.4 IU/mL at inclusion.&#xD;
&#xD;
          5. Patients susceptible to epilepsy seizure.&#xD;
&#xD;
          6. Patients with pacemaker.&#xD;
&#xD;
          7. Patients refusing to wear retinal goggles during low-level laser 1. Patients with a&#xD;
             solid cancer lesion in the area of low-level laser application.&#xD;
&#xD;
          8. Patients protected by law (guardianship and safeguarding of justice).&#xD;
&#xD;
          9. Pregnant female patients as determined by positive serum pregnancy test at screening.&#xD;
&#xD;
         10. Lactating female patients who are actively breast feeding.&#xD;
&#xD;
         11. Participation in another clinical trial involving oral care.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlène PASQUET</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlène PASQUET, MD</last_name>
    <phone>05 34 55 86 43</phone>
    <phone_ext>+33</phone_ext>
    <email>pasquet.m@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gwennaëlle ALPHONSA, CRA</last_name>
    <phone>05 67 77 13 94</phone>
    <phone_ext>+33</phone_ext>
    <email>alphonsa.g@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Occitanie</state>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marlène PASQUET, MD</last_name>
      <phone>0534558643</phone>
      <phone_ext>+33</phone_ext>
      <email>pasquet.m@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Gwennaëlle ALPHONSA, CRA</last_name>
      <phone>05 67 77 13 94</phone>
      <phone_ext>+33</phone_ext>
      <email>alphonsa.g@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Cécile BOULANGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle PELLIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle PELLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastien KLEIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sebastien KLEIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominique PLANTAZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique PLANTAZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Wadih ABOU CHAHLA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wadih ABOU CHAHLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline OUDOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Caroline OUDOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arthur STERIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arthur STERIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie VALDUGA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julie VALDUGA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marilyne POIREE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marilyne POIREE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Armand Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine DOLLFUS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine DOLLFUS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Chrystelle DUPRAZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chrystelle DUPRAZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Claire PLUCHART, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claire PLUCHART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie JAFFRAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandrine THOUVENIN -DOULET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sandrine THOUVENIN -DOULET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine PAILLARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine PAILLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julien, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julien LEJEUNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Oral mucositis</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Photobiomodulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

